Osimertinib plus chemotherapy versus osimertinib for patients with advanced NSCLC with concomitant EGFR and TP53 mutations: a prospective cohort study.
奥希替尼联合化疗与奥希替尼单药治疗伴有 EGFR 和 TP53 突变的晚期 NSCLC 患者的疗效比较：一项前瞻性队列研究
期刊:Scientific Reports
影响因子:3.9
doi:10.1038/s41598-025-03422-9
Li Jixian, Zhan Xiang, Shao Mengqing, Zeng Renya, Li Jianan, Zhu Hui, Feng Alei, Yang Zhe, Jing Wang
